RNA (Atrium Therapeutics) Effective Interest Rate on Debt %: 0.00% (As of Mar. 2026)


RNA Atrium Therapeutics Inc RNA
12 GF Score
Price $13.30
! 1 Warning Sign
View Full Analysis

What is Atrium Therapeutics Effective Interest Rate on Debt %?

Atrium Therapeutics RNA -0.97% 12 Effective Interest Rate on Debt % is 0.00% as of Mar. 2026. GuruFocus rates RNA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Atrium Therapeutics's annualized positive value of Interest Expense for the quarter that ended in Mar. 2026 was $0.00 Mil. Atrium Therapeutics's average total debt for the quarter that ended in Mar. 2026 was $3.18 Mil. Therefore, Atrium Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2026 was 0.00%.

Atrium Therapeutics  (NAS:RNA) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

Atrium Therapeutics Effective Interest Rate on Debt % Related Terms

Atrium Therapeutics Effective Interest Rate on Debt % Historical Data

* Premium members only.

The historical data trend for Atrium Therapeutics's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atrium Therapeutics Effective Interest Rate on Debt % Chart

Atrium Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Effective Interest Rate on Debt %
0.00 0.00 0.00

Atrium Therapeutics Quarterly Data
Dec23 Dec24 Mar25 Sep25 Dec25 Mar26
Effective Interest Rate on Debt % Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

RNA vs CNTN, QTTB, TARA: Effective Interest Rate on Debt % Comparison

For the Biotechnology subindustry, Atrium Therapeutics's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atrium Therapeutics Effective Interest Rate on Debt % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atrium Therapeutics's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Atrium Therapeutics's Effective Interest Rate on Debt % falls into.


RNA
12GF Score
Atrium Therapeutics Inc RNA
Effective Interest Rate on Debt % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atrium Therapeutics Effective Interest Rate on Debt % Calculation

Atrium Therapeutics's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2025 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2024 )+Total Debt  (A: Dec. 2025 ))/ count )
=-1  *  0/( (6.801+3.672)/ 2 )
=-1  *  0/5.2365
=0.00 %

where

Total Debt  (A: Dec. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=2.957 + 3.844
=6.801

Total Debt  (A: Dec. 2025 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0 + 3.672
=3.672

Atrium Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2026 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Dec. 2025 )+Total Debt  (Q: Mar. 2026 ))/ count )
=-1  *  0/( (3.672+2.68)/ 2 )
=-1  *  0/3.176
=0.00 %

where

Total Debt  (Q: Dec. 2025 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0 + 3.672
=3.672

Total Debt  (Q: Mar. 2026 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0 + 2.68
=2.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Mar. 2026) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

What does a Effective Interest Rate on Debt % of 0.00% mean?
Atrium Therapeutics (RNA) has a Effective Interest Rate on Debt % of 0.00% as of Mar. 2026. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Atrium Therapeutics and its competitors.
Is Atrium Therapeutics' Effective Interest Rate on Debt % too high?
Atrium Therapeutics' current Effective Interest Rate on Debt % is 0.00%. Overall, Atrium Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Atrium Therapeutics' Effective Interest Rate on Debt % compare to CNTN and QTTB?
Atrium Therapeutics' Effective Interest Rate on Debt % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Effective Interest Rate on Debt % for a Biotechnology company?
A good Effective Interest Rate on Debt % depends on the Biotechnology industry context. However, Effective Interest Rate on Debt % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Effective Interest Rate on Debt % mean?
A high Effective Interest Rate on Debt % can signal that a stock is expensive relative to its fundamentals. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Atrium Therapeutics and its competitors. Atrium Therapeutics's current Effective Interest Rate on Debt % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrium Therapeutics stock overvalued right now?
Atrium Therapeutics (RNA) has a current Effective Interest Rate on Debt % of 0.00%. The current Effective Interest Rate on Debt % is 0.00%. Atrium Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Effective Interest Rate on Debt % calculated?
Effective Interest Rate on Debt % is calculated from a company's financial statements. For Atrium Therapeutics (RNA), the current Effective Interest Rate on Debt % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atrium Therapeutics Business Description

Address 10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
12GF Score

Get the complete analysis for RNA

Effective Interest Rate on Debt % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.30
Price